Reference no: EM133333348
Questions:
1. Explain how polio virus is transmitted- additionally:
a. why was a bivalent oral polio vaccine (bOPV) chosen as a key strategic tool?
b. What were the key steps in the development of bOPV?
c. Who were the key stakeholders involved in both bOPV development and implementation?
2. How did the development of bOPV align with evolving programatic needs? What were vaccination tools available to rthe global polio eradication initiative prior to bOPV? Why were new strategies required for the polio eradication program and remaining endemic countries? What was the programatic impact of the bOPV introduction?
3. What were the key stages from a product lifecycle perspective that have to be addressed in the development of bOPV?
4. How did the WHO coordinate the accelerated clinical trial and production of bOPV? Why was India selected as the location for the clinical trial? Why was the clinical trial able to bypass phase 1 and 2? Why and how did the WHO engage drug manufacturers and national regulatory authorities?
5. Base on what you have learned about reimbursement in week 11 of the course how would manufacturers go about determining the fair price for the vaccines mentioned in this case? How about a Covid 19 vaccines for which the benefits of utilization outweigh the potential risk from a safety perspective?
6. What can the global health community leverage from this experience that can be utilized during the current covid 19 pandemic? Additionally what other diseases could benefit from the lessons learned in vaccine development from this case?